Two nationally recognized experts in cloning and stem cell science from the University of Houston are taking the first step toward limiting the consequences of chronic inflammation in cystic fibrosis (CF) by identifying the source of this persistent and enigmatic inflammation in CF lungs.
Acute lower respiratory infection caused by Respiratory Syncytial Virus (RSV) contributes substantially to the global mortality burden in children, with RSV estimated to cause one in 50 deaths among children under five, and one in 28 deaths among children under six months.
Brensocatib did not improve the clinical status of patients hospitalized with severe SARS-CoV-2 infection in the double-blind randomized, placebo-controlled STOP-COVID19 multicenter clinical trial, according to research published at the ATS 2022 international conference.
Researchers at the Abramson Cancer Center at the University of Pennsylvania have found a way to identify lung cancer at the cellular level in real time during a biopsy, offering promise in the ability to detect the disease earlier and with more confidence. The research is published this week in Nature Communications.
Avacopan was better than prednisone in reducing respiratory as well as ear, nose and throat (ENT) involvement and enabled reduced glucocorticoid use in ANCA-associated vasculitis patients participating in the phase 3 ADVOCATE trial. Study results were published at the ATS 2022 international conference. The study was a subgroup analysis of results from the larger trial, which led to FDA approval of avacopan.
The first study to look at follow-up for patients deemed at high risk for lung cancer after CT screening found that 47 percent delayed follow-up care, according to research published at the ATS 2022 international conference.
Today at its annual Membership Meeting, the slate of officers to serve on the American Thoracic Society’s Executive Committee for the 2021-2022 term were approved by the membership.
Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe COVID-19.
UC Davis Health physicians have performed the first single anesthesia diagnosis to treatment of lung cancer utilizing a fully robotic approach in the UC Health System. Procedure allows physicians to diagnose and remove lung cancer mass during single surgery.
In comparison to data about video-assisted (VATS) lobectomy, retrospective data about robotic-assisted (RTS) lobectomies show such benefits as decreased postoperative pain, lower mortality, shorter chest tube duration, shorter hospital stays, and reduced incidences of postoperative pulmonary complications.
The Pulmonary Fibrosis Foundation (PFF) has developed new materials and tools for people living with pulmonary fibrosis (PF) to learn about and enroll in
clinical research studies.
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab than placebo, according to research published at the ATS 2022 international conference. The study showed that nearly half of those enrolled achieved complete response to treatment across measures of exacerbation reduction, asthma control, lung function, and clinician assessment.
A study presented today at the AATS 102nd Annual Meeting reports that intentionally prolonging the cold static preservation (CSP) of a donor lung at 10°C (12-24h) is clinically safe and feasible.
The Pulmonary Fibrosis Foundation announced research results from four studies examining access to care and outcomes for patients living with pulmonary fibrosis and interstitial lung disease.
A significant percentage of Black men found to have normal lung function after race-based adjustments to spirometry were actually found to have emphysema on their computed tomography (CT) scans, according to research published at the ATS 2022 international conference.
New research led by scientists at the American Cancer Society shows the need for continued surveillance of the changes in shopping interest and sales for Puff Bar, the most preferred brand of electronic cigarettes or e-cigarettes among youth in the United States. Public interest in shopping and sales of Puff Bar skyrocketed in 2020.
Researchers show that severe inflammation during hospitalization for Covid-19 increases risk of death within one year from seeming recovery by 61%. This risk is mitigated if anti-inflammatory steroids are prescribed upon discharge. We need to think of Covid-19 as a potentially chronic disease that requires long-term management, argue the authors.
A new study in JNCCN finds patients with cancer who smoke are more likely to receive evidence-based cessation assistance by using the ELEVATE program, increasing the likelihood of better outcomes.
The May 2022 issue of Toxicological Sciences, the Society of Toxicology’s official journal, is now available and features leading research in carcinogenesis, computational toxicology and databases, and more.
Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.
Almost four years since the last guidance on the diagnosis and management of idiopathic pulmonary fibrosis, the American Thoracic Society – in collaboration with the European Respiratory Society, Japanese Respiratory Society and Asociacion Latinoamericana de Torax – has issued new guidelines for clinicians. The guidelines are available online in the May 1 issue of the American Journal of Respiratory and Critical Care Medicine.
Get a sneak-peak at what’s coming up at the ATS 2022 International Conference later this month with today’s online release of the Abstract Issue of the American Journal of Respiratory and Critical Care Medicine.
It’s been 50 years since the Tuskegee Study was disclosed to the American public. In May, a new riveting account of the Study, when government doctors intentionally withheld effective therapy for syphilis for 40 years in 400 African American men, will be published in the American Journal of Respiratory and Critical Care Medicine. The article explains the deeper everlasting lessons of the study.
A new study projects that a U.S. ban on menthol cigarettes, proposed by the U.S. Food and Drug Administration, will lead more than 1.3 million smokers to quit.
An online breathing and wellbeing programme helps improve quality of life and breathlessness for people recovering from COVID-19, according to a new study.
Six in ten people with COVID-19 still have at least one symptom a year later, a new study being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal (23-26 April) has found.
The 2022 Annual Report from the Smidt Heart Institute at Cedars-Sinai is available now, detailing the latest research and medical achievements by the expert team ranked No. 1 for cardiology and cardiac surgery in California by U.S. News & World Report.
Working with an international team of leading intensive care clinicians, engineering researchers at the University of Warwick have used computational modelling to show that non-invasive respiratory support is more likely to be successful if it allows significant reductions in patients’ breathing efforts.
A surgically implanted device that moves the tongue forward during sleep was found to safely and effectively reduce sleep apnea in adolescents with Down syndrome, according to a new study published April 21 in JAMA Otolaryngology – Head & Neck Surgery.
Research over the past two years has shown that, contrary to early opinion, asthma doesn’t seem to make COVID-19 more severe or deadly for those who suffer from the disease.
A new University of Gothenburg study has paved the way for the first drug treatment for sleep apnea. Compared to before receiving the treatment, breathing pauses decreased with on average more than 20 per hour for patients given the drug.
Higher levels of silica dust can be found in the lung tissue of contemporary coal miners compared to the lung tissue in previous generations of coal miners, according to a new study in the Annals of the American Thoracic Society. The study helps explain the recent increase in severe pneumoconiosis – often referred to as black lung disease – concentrated in central Appalachia (West Virginia, Virginia and Kentucky) miners.
With the aid of a $3.5 million National Institutes of Health grant (R01HL158850), investigators from Rutgers Cancer Institute of New Jersey – the state’s only National Cancer Institute-designated Comprehensive Cancer Center – along with Holden Cancer Center at the University of Iowa, and the University of Texas MD Anderson Cancer Center, are collaborating on a project to address lung cancer screening disparities among individuals with a history of heavy smoking.
Silica exposure is a driving force behind rising rates of coal workers' pneumoconiosis, according to a new study that compared the pathology and mineralogy of the disease across generations. It is the first study to offer scientific evidence explaining why progressive massive fibrosis, the most severe form of black lung disease, is occurring more frequently and among younger coal workers in West Virginia, Virginia and Kentucky.
The National Institutes of Health (NIH) and the National Institute on Aging recently approved funding for a 2022 study by the Institute for Exercise and Environmental Medicine (IEEM), where a research team will look into how body weight – even extra weight gain like the kind recently resulting from the COVID-19 pandemic – may adversely affect breathing in seniors.
The ATS 2022 International Conference is coming back strong! Whether you cover clinical medicine or research, the programming at ATS 2022 is an extensive roundup of the latest in pulmonary, critical care and sleep medicine.
How do the lungs develop after taking their first breaths outside the womb? What cellular events and changes early in life give rise to lung malfunction and disease? To help answer these questions, scientists have constructed the first single-cell atlas of postnatal lung development in humans and mice. The research could help provide a more detailed understanding—at the level of individual cells—of which genetic and epigenetic factors affect lung health across the human lifespan, starting from birth.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer.
Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.
Cigarette smoking is overwhelmingly the main cause of lung cancer, yet only a minority of smokers develop the disease. A study led by scientists at Albert Einstein College of Medicine and published online today in Nature Genetics suggests that some smokers may have robust mechanisms that protect them from lung cancer by limiting mutations. The findings could help identify those smokers who face an increased risk for the disease and therefore warrant especially close monitoring.
A study shows statistically significant and potentially clinically important differences between those who increased and decreased tobacco use during the pandemic. Among current smokers, 28.2 percent reported increased tobacco use, 17.3 percent reported decreased tobacco use and 54.5 percent reported no change.
New data to be presented by Grace Dy, MD, at the American Association for Cancer Research Annual Meeting show that patients with non-small cell lung cancer (NSCLC) who received the targeted therapy sotorasib experienced extended survival and good quality of life.
Due to COVID-19 and a rapidly expanding list of conditions for which lung transplantation can be lifesaving, the need for new organs is growing. However, there’s a global shortage of donated lungs, which results in numerous deaths among patients on the waitlist. To help expand the donor pool, Northwestern Medicine is now using a device from XVIVO called XPS™ which is used for ex vivo lung perfusion (EVLP) – nicknamed “lungs in a box” – to rescue potentially viable lungs and those initially deemed “unacceptable” for transplant. Out of all solid organs, lungs have the lowest utilization, with only one in five donated lungs getting transplanted.